Peptides for Reproductive Health
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 16, 2026
Comprehensive guide to 22 peptides researched for reproductive health, ranked by evidence strength from FDA-approved to early preclinical. Each compound is evaluated on mechanism, clinical status, and safety profile.
Overview
22 research peptides are currently studied for reproductive health. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Gonadorelin — FDA Approved
Evidence Rating: A
Category: Reproductive / Hormonal
Gonadorelin is a synthetic decapeptide identical to the naturally occurring gonadotropin-releasing hormone (GnRH) produced in the hypothalamus. It stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which regulate testosterone production in men and ovulation in women. It is used clinically for diagnostic testing of pituitary function, and in pulsatile administration for certain infertility conditions. In the peptide community, it is commonly discussed as a complement to testosterone replacement therapy to maintain testicular function and fertility.
Key claims: Maintains testicular function during TRT; Restores fertility in hypothalamic amenorrhea.
Oxytocin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Oxytocin is an endogenous cyclic nonapeptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 with a disulfide bridge between Cys1 and Cys6, MW ~1007.2 g/mol) produced in the hypothalamus and released from the posterior pituitary. Synthetic oxytocin (Pitocin) is one of the most widely used medications in obstetrics, FDA-approved for labor induction and augmentation, and for control of postpartum hemorrhage. It acts on oxytocin receptors in the uterine myometrium to stimulate rhythmic contractions and on mammary myoepithelial cells to facilitate milk ejection.
Key claims: Induces and augments labor effectively; Prevents and treats postpartum hemorrhage.
Vasopressin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Vasopressin (arginine vasopressin, AVP) is an endogenous cyclic nonapeptide hormone (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2, MW ~1084.2 g/mol) synthesized in the hypothalamus and released from the posterior pituitary. It regulates water reabsorption in the renal collecting ducts via V2 receptors and mediates vasoconstriction via V1a receptors. Synthetic vasopressin (Vasostrict) is FDA-approved for vasodilatory shock and has been used for diabetes insipidus, esophageal variceal bleeding, and cardiac arrest.
Key claims: Effective in vasodilatory shock; Used in cardiac arrest algorithms.
Desmopressin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of vasopressin (MW ~1069.2 g/mol) with enhanced V2 receptor selectivity and resistance to enzymatic degradation. It is FDA-approved for central diabetes insipidus, hemophilia A (with factor VIII levels >5%), type 1 von Willebrand disease, and primary nocturnal enuresis. Desmopressin is available as injectable, intranasal, oral tablet, and sublingual formulations, making it one of the most versatile peptide medications in clinical use.
Key claims: Effectively treats central diabetes insipidus; Raises factor VIII and VWF levels in mild hemophilia A.
Terlipressin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Terlipressin is a synthetic vasopressin analog (MW ~1227.4 g/mol) that acts as a prodrug, slowly converted by tissue peptidases to the active metabolite lysine vasopressin. It was FDA-approved in September 2022 (Terlivaz) for hepatorenal syndrome type 1 (HRS-1), making it the first pharmacotherapy specifically approved for this indication in the United States. Terlipressin has been used in Europe for decades for variceal bleeding and hepatorenal syndrome. It acts primarily via V1a receptors to cause splanchnic vasoconstriction, improving renal perfusion in the context of portal hypertension.
Key claims: Improves renal function in hepatorenal syndrome type 1; First FDA-approved therapy for hepatorenal syndrome.
Carbetocin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Carbetocin is a long-acting synthetic analog of oxytocin (MW ~1041.2 g/mol) with a half-life of approximately 40 minutes, roughly 4-10 times longer than oxytocin. It is included on the WHO Model List of Essential Medicines for prevention of postpartum hemorrhage (PPH). Carbetocin is approved in over 30 countries for the prevention of uterine atony and PPH following cesarean delivery. A heat-stable formulation was developed to enable use in low-resource settings where cold chain maintenance is challenging.
Key claims: Prevents postpartum hemorrhage after cesarean section; Heat-stable formulation effective in tropical settings.
Leuprolide — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Leuprolide (leuprorelin) is a synthetic GnRH (gonadotropin-releasing hormone) agonist nonapeptide (MW ~1209.4 g/mol) that is one of the most widely prescribed hormonal therapies in oncology and reproductive medicine. It is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and as part of assisted reproductive technology protocols. Available as depot injections (monthly, 3-month, 4-month, 6-month) and subcutaneous implants, leuprolide provides sustained GnRH receptor stimulation leading to desensitization and profound suppression of gonadotropins and sex steroids.
Key claims: Effective androgen deprivation therapy for prostate cancer; Treats endometriosis-associated pain.
Goserelin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Goserelin is a synthetic GnRH agonist decapeptide analog (MW ~1269.4 g/mol) delivered as a biodegradable PLGA implant (Zoladex) injected subcutaneously in the anterior abdominal wall. It is FDA-approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablation. Like other GnRH agonists, goserelin operates through a "flare then suppression" mechanism, achieving castrate levels of sex steroids with continued administration. The implant formulation is available in 1-month (3.6 mg) and 3-month (10.8 mg) presentations.
Key claims: Effective androgen deprivation in prostate cancer; Adjuvant treatment for premenopausal breast cancer.
Triptorelin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Triptorelin is a synthetic GnRH agonist decapeptide analog (MW ~1311.4 g/mol) with a D-Trp substitution at position 6 of native GnRH. It is FDA-approved for the palliative treatment of advanced prostate cancer (Trelstar) and for central precocious puberty (Triptodur). Available as intramuscular depot injections in 1-month (3.75 mg), 3-month (11.25 mg), and 6-month (22.5 mg) formulations. Like other GnRH agonists, it operates through initial pituitary stimulation followed by receptor downregulation and gonadotropin suppression.
Key claims: Achieves effective castration in prostate cancer; Effectively suppresses puberty in central precocious puberty.
Nafarelin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Nafarelin is a synthetic GnRH agonist decapeptide analog (MW ~1322.5 g/mol) with a D-Nal(2) substitution at position 6, administered as a nasal spray (Synarel). It is FDA-approved for the treatment of endometriosis and central precocious puberty. Nafarelin is approximately 200 times more potent than native GnRH and is unique among GnRH agonists in its intranasal route of administration, which avoids injections entirely. Like other GnRH agonists, it achieves sex steroid suppression through the "flare then suppression" mechanism.
Key claims: Effectively treats endometriosis pain; Suppresses puberty in central precocious puberty.
Histrelin — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Histrelin is a synthetic GnRH agonist nonapeptide analog (MW ~1323.5 g/mol) with a D-His(benzyl) substitution at position 6. It is FDA-approved as a subdermal implant for advanced prostate cancer (Vantas, 50 mg implant releasing ~50 mcg/day for 12 months) and central precocious puberty (Supprelin LA, 50 mg implant releasing ~65 mcg/day for 12 months). The hydrogel implant technology provides consistent drug delivery for a full year, offering the longest interval between doses of any GnRH agonist formulation.
Key claims: Provides 12 months of continuous testosterone suppression; Effective long-term treatment for central precocious puberty.
Degarelix — Approved Medication with Strong Human Data
Evidence Rating: A
Category: Reproductive / Hormonal
Degarelix is a synthetic GnRH antagonist (MW ~1632.3 g/mol) and the first injectable GnRH receptor blocker approved for advanced prostate cancer. FDA-approved in 2008 (Firmagon), it produces immediate suppression of LH, FSH, and testosterone without the initial hormonal flare seen with GnRH agonists. This is clinically significant in patients where testosterone flare could cause complications such as spinal cord compression, urinary obstruction, or bone pain exacerbation. Degarelix is administered as a monthly subcutaneous injection.
Key claims: Achieves rapid testosterone suppression without flare; Non-inferior to leuprolide for testosterone suppression.
Shop Research Peptides
HCG 5,000iu
Melanotan I 10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Gonadorelin vs HCG: Comparing GnRH Analogues in Reproductive Research
Compare gonadorelin vs HCG in reproductive research. Mechanisms, preclinical evidence, and limitations for GnRH analogue studies.
Oxytocin's Vital Role in Social and Relationship Bonds
Oxytocin, known as the love hormone, supports social connections through release during touch, trust, and intimacy. Research indicates it aids trust, empathy, and bonding in romantic, parental, and friendly relationships, though effects depend on context and individual factors. This peptide also interacts with stress systems to promote emotional regulation and well-being.
Atosiban Serves as Maintenance Therapy for Preterm Labor
Atosiban, an oxytocin-receptor antagonist marketed in China in 2006, offers maintenance treatment to manage preterm labor risks after initial tocolysis. Clinical trials show it delays delivery better than placebo in some cases and has fewer side effects than beta-2 agonists. Studies highlight its safety and role in reducing recurrent preterm labor episodes.
Peptide Tools
Key research references
- Best Peptides for Anti-Aging | Research Guide
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
SubscribeFrequently Asked Questions
Related Research
About the reviewer
Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 16, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.